Health conditions
GLP-1s and birth control: what the labels say
October 2, 2026 · 6 min read · Medically reviewed by Bryan Milton, MD · Reviewed October 2, 2026
The tirzepatide labels advise extra contraceptive precautions around starting treatment and each dose increase. What that means in practice, and why.
This is one of the most consequential practical items on the tirzepatide label and one of the least known. If you take an oral contraceptive and are starting or increasing tirzepatide, it applies to you directly.
What the labels say
The approved tirzepatide labels state that tirzepatide can reduce the efficacy of oral hormonal contraceptives, and advise patients using them either to switch to a non-oral contraceptive method, or to add a barrier method, for four weeks after starting treatment and for four weeks after each dose increase.
The approved semaglutide labels do not carry that specific advice. That difference is real and worth knowing which side of you are on — but it is not a reason to skip the conversation if you take semaglutide, because pregnancy prevention matters either way.
Why does it happen?
Delayed gastric emptying. An oral contraceptive has to be absorbed from the gut, and a medication that slows how quickly the stomach empties can change how much is absorbed and when. The effect is most relevant when the degree of delay is changing — which is exactly at the start of treatment and after each dose step.
What this means in practice
| When | What the label advises |
|---|---|
| Starting treatment | A non-oral method, or add a barrier method, for four weeks |
| After each dose increase | The same four-week precaution again |
| Between increases on a stable dose | The label's precaution is tied to those windows |
| Considering a long-term switch | A non-oral method avoids the issue entirely — discuss it |
Non-oral options that do not depend on gut absorption include intrauterine devices, implants, injections, patches and rings, as well as barrier methods. Which is appropriate is a conversation with a clinician who knows your history.
Why pregnancy prevention matters here
Because these medications are not for use in pregnancy. The approved labels address stopping before a planned pregnancy, and that involves lead time rather than being something to do the week you decide. An unplanned pregnancy on a GLP-1 is precisely the situation the contraceptive advice exists to prevent — which is why a label footnote about absorption is actually a significant clinical instruction.
What to tell your clinician
- Exactly what contraception you use, including the type and how long you have used it.
- Whether you might want to become pregnant, and roughly when.
- Any history of pregnancy complications or conditions affecting contraceptive choice.
- Anything else you take, since interactions can run both ways.
If you become pregnant while taking a GLP-1, or think you might be, contact your clinician promptly. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. The labelled advice applies to compounded preparations of the same molecule, and GLP's clinicians screen against it.
Whether a GLP-1 is appropriate for you, with your particular history and medications, is a decision for a licensed clinician who has reviewed them. This article is here so you know what to raise, not so you can conclude.
This article is educational and is not a substitute for personalized medical advice. Whether any medication is appropriate for you is a decision for a licensed clinician who has reviewed your health history.